Haemodialysis is a medical procedure that involves the removal of fluids and waste products from the blood. This is accomplished by using a dialysis machine and a dialyzer. It is used to treat both acute and chronic kidney failure.
The global haemodialysis equipment market is driven by in the number of End-Stage Renal Disease (ESRD) patients owing to the growing prevalence of diabetes, hypertension, and an increasingly large elderly population. ESRD is the most severe form of renal failure where kidneys permanently cease to function and the affected person loses the adequate kidney function necessary to sustain life.
Download free sample: https://www.datamintelligence.com/download-sample/haemodialysis-equipment-market
The major drivers fueling the growth of the market are the increasing number of ESRD patients, and a significant rise in number of dialysis centres. The restraints that pull down the haemodialysis market are rising cases of kidney transplants and the advent of newer approaches like artificial kidneys.
Increasing number of ESRD (end-stage renal disorder) patients require continuous support via dialysis, hence driving market growth
ESRD patients have been steadily increasing across the world. They are the biggest end users of dialysis, as their kidneys have lost much of their functionality. The burden of ESRD will increase in the United States population through 2030 due to demographic, clinical, and lifestyle shifts in the population and improvements in RRT. Planning for ESRD resource allocation should allow for substantial continued growth in the population of patients with ESRD. Future interventions should be directed to preventing the progression of CKD to kidney failure. The increase in ESRD incidence rates within age and race groups has leveled off and/or declined in recent years, but our model indicates that population changes in age and race distribution, obesity and diabetes prevalence, and ESRD survival will result in a XX% increase in the crude incidence rate from 2020 to 2030.
Increase in the number of kidney transplants will reduce the haemodialysis market share
People with kidney failure need dialysis or a kidney transplant to stay alive. After a kidney transplantation, they no longer require dialysis to survive. The number of kidney transplants increased by XX% in the year 2019 and will show strong growth. Multiple factors could explain this increase. The narcotics overdose epidemic is unending, and has created demand for almost one-third of these transplants. Another reason for the upward trend is the increased use of organs harvested from patients following cardiac death and not just from those who suffer brain death. Organs donated after cardiac death account for about 20% of organ donations. In addition, organ procurement organizations have excelled at at identifying donors, and have broadened the population of donors that they are willing to consider for donation. Those organs which were not considered in the past are now acceptable. Even after an increase in the supply of kidneys, the demand is still unmet, with XX patients awaiting kidney transplants at any given moment in North America.
Global Haemodialysis Equipment Market – By Modality
Global Haemodialysis Equipment Market – By Product Type
Global Haemodialysis Equipment Market – By End User
Global Haemodialysis Equipment Market – By Region
Some of the key players in the market are Fresenius Medical Care, DaVita Healthcare Partners, Baxter International, B. Braun Melsungen, Nipro Corporation, Diaverum Deutschland GmbH, Nikkiso Co. Ltd., and NxStage Medical.
The major companies in the market are focusing high on R&D, product innovation, an extension of the existing product line and looking to strengthening the market presence by geographical expansion. For instance, in January 2019, Baxter International Inc. got FDA approval for its clinical trial on on-demand peritoneal dialysis solution generation system. The new system offers a good platform for patients to perform peritoneal dialysis at home. In September 2017, Fresenius Medical Care started new manufacturing facility in Malaysia. The strategic move was taken by company to accelerate the production of advanced continuous ambulatory peritoneal dialysis materials.